Price List - Gywn Lo - Contraceptive Agents - Misc.xlsx
XLSX spreadsheet 44 KB Posted
- Solicitation number
- HT9402-26-Q-9403
- Issued by
-
Defense Health Agency
About this file
This is a pricing template for the Department of War (DoW) Pharmacy and Therapeutics (P&T) Committee's November 2026 review of newly approved contraceptive agents in the miscellaneous subclass. The price list is designated for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) procurement under solicitation HT9402-26-Q-9403 issued by the Defense Health Agency. The template covers ten newly approved drug entries, each requiring pricing submissions for both Uniform Formulary (UF) and Non-Formulary (NF) scenarios with no step therapy requirements at military treatment facilities and mail order venues. Manufacturers must submit quotes with price per NDC package size and price per unit, along with a completed Quote Review Checklist and fully executed signature pages by the deadline of September 24, 2026.
The pricing template includes multiple pricing appendices addressing different reimbursement mechanisms: BPA pricing (fixed price per unit of measure across all package sizes), ADP non-FAMP discount pricing (calculating total refunds based on non-FAMP price plus additional manufacturer discounts), and ADP WAC discount pricing (for products without Federal Ceiling Pricing using Wholesale Acquisition Cost from First Databank). For TRICARE retail refunds under the ADP sections, manufacturers must provide pricing for Tier 2 and Tier 3 formulary categories. A prior authorization may apply per class notes, and the P&T Committee meeting is scheduled for November 4-5, 2026, with a pre-quotation teleconference on September 9, 2026.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Formulary Placement of FDA NADs.pdf | ||
| RFQ HT9402-26-Q-9403 NAD.pdf | ||
| Price List - Furoscix ReadyFlow - Diuretics - NA.xlsx | XLSX spreadsheet | |
| Price List - Jideytro - Lung Cancer - NA.xlsx | XLSX spreadsheet | |
| Price List - Zenbexus - Multiple Myeloma - NA.xlsx | XLSX spreadsheet | |
| Price List - Omlyclo - Atopy - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - RizaFilm - Migraine Agents - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. |
Step Therapy Addendum: N/A
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 162OCMUN0UFNS1M | Uniform Formulary | |||
| No Step Therapy | 1 or more | NO QUOTE | |||
| 162OCMUN0NFNS1M | Non-Formulary | ||||
| No Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. |
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. |
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | CONTRACEPTIVE AGENTS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | MISCELLANEOUS | Quotes due: | September 24, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 162OCMUN0T2NS1M | Tier 2 | |||
| No Step Therapy | 1 or more | ||||
| 162OCMUN0T3NS1M | Tier 3 | ||||
| No Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .